ICATT Publications and Awards

ICATT manuscripts published

• Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024 | MMWR
  Link-Gelles R, Ciesla AA, Mak J, et al.
  MMWR Morb Mortal Wkly Rep. 2024;73(4):77-83.

• Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions.
  Link-Gelles R, Britton A, Fleming-Dutra KE, for the CDC COVID-19 Vaccine Effectiveness Team.
  Vaccine. 2023, Epub.

• Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3-5 Years – Increasing Community Access to Testing Program, United States, July 2022-February 2023.
  Fleming-Dutra KE, Ciesla AA, Roper LE, et al.
  MMWR Morb Mortal Wkly Rep. 2023;72(7):177-182.

• Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods.
  Ciesla AA, Wiegand RE, Smith ZR, et al.
  Open Forum Infectious Disease. 2023, Epub.

• Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023.
  Link-Gelles R, Ciesla AA, Roper LE, et al.
  MMWR Morb Mortal Wkly Rep. 2023;72(5):119–124.

• Spike Gene Target Amplification in a Diagnostic Assay as a Marker for Public Health Monitoring of Emerging SARS-CoV-2 Variants — United States, November 2021–January 2023.
  Scobie HM, Ali AR, Shirk P, et al.
  MMWR Morb Mortal Wkly Rep. 2023;72(5):125–127.

• Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022.
  Link-Gelles R, Ciesla AA, Fleming-Dutra KE, et al.
  MMWR Morb Mortal Wkly Rep. 2022;71(48):1526-1530.

• Effectiveness of homologous and heterologous Covid-19 boosters against Omicron
  Accorsi, E. K., Britton, A., Shang, N., Fleming-Dutra, K. E., Link-Gelles, R., Smith, Z. R., ... & Verani, J. R.
  New England Journal of Medicine. 2022;386(25):2433-2435.

• Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance
  Fleming-Dutra, K. E., Britton, A., Shang, N., Derado, G., Link-Gelles, R., Accorsi, E. K., ... & Schrag, S. J.
  JAMA. 2022;327(22):2210-2219.

• Association of COVID-19 vaccination with symptomatic SARS-CoV-2 infection by time since vaccination and Delta variant predominance
  Britton, A., Fleming-Dutra, K. E., Shang, N., Smith, Z. R., Dorji, T., Derado, G., ... & Verani, J. R.
  JAMA. 2022;327(11):1032-1041.

• Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants
  Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G., ... & Verani, J. R.
  JAMA. 2022;327(7):639-651.

• The Impact of Community-Based Testing Sites and Gift Incentives on COVID-19 Testing Uptake in Maryland, April 29 – May 9, 2021
  Turbyfill C, Thomas I, Agravat N, et al.
  Am J Health Promot., 2022;37(2):228-232.

• Community-Based Testing Sites for SARS-CoV-2 — United States, March 2020–November 2021 | MMWR
  Miller MF, Shi M, Motsinger-Reif A, et al.
  MMWR Morb Mortal Wkly Rep. 2021;70(49):1706-1711.

ICATT awards

• 2024 ORR Honor Award – Excellence in Health Equity
• 2024 FORUM Innovation Award
• 2023 NCIRD Honor Award for Excellence in Public Health Impact
• 2023 Charles C. Shepard Science Awards – Prevention and Control
  • Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G., ... & Verani, J. R. JAMA. 2022;327(7):639-65

• 2022 CDC and ORR Honor Award for Program Delivery – Domestic

• 2022 ORR Honor Award for Frontline Public Health Service

• 2022 ORR Honor Award for Health Equity

• 2021 CDC's COVID-19 Honor Award for Excellence in Finance

• 2020 CDC/ATSDR Honor Award for Excellence in Partnering – Domestic (COVID-19 selections): Testing and Diagnostic Working Group/ State Technical Assistance Team